Skip to main content
SpringerLink
Log in

Oral Chemotherapy Agents in the Treatment of Leukaemia

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oral chemotherapy agents have been an important component of the treatment of leukaemia for many years. Obstacles such as poor or erratic bioavailability and noncompliance have often limited the utility of oral agents in the treatment of leukaemia. However, recent evaluations of new or existing oral agents have expanded the clinician’s options and understanding of the use of these drugs in the treatment of leukaemia. One major advance is the use of tretinoin (all-trans retinoic acid) in the treatment of acute promyelocytic leukaemia (APL). Tretinoin, an oral vitamin A derivative that reverses abnormal differentiation in APL is now an essential component of first-line therapy for APL, replacing standard intravenous chemotherapy induction regimens. Other advances include an increased understanding of the pharmacokinetic and pharmacodynamic profile of oral chemotherapy agents such as etoposide and high dose busulfan, allowing for modifications or individualisation of administration regimens to enhance efficacy or minimise toxicity. Evaluations of noncompliance with oral agents in the treatment of leukaemia have also provided the clinician with important information on how this obstacle to oral therapy may be overcome or minimised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bustamante CI, Wade JC. Herpes simplex viras infection in the immunocompromised cancer patient. J Clin Oncol 1991; 9: 1903–15

    PubMed  CAS  Google Scholar 

  2. Ptachcinski RJ, Burckart GJ, Venkataramanan R. Cyclosporine. Drag Intell Clin Pharm 1985; 19: 90–100

    CAS  Google Scholar 

  3. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998; 16: 2557–67

    PubMed  CAS  Google Scholar 

  4. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374–7

    PubMed  CAS  Google Scholar 

  5. Smyth RD, Pfeffer M, Scalzo A, et al. Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 1985; 12 Suppl. 2: 48–51

    PubMed  CAS  Google Scholar 

  6. Herbert MF, Roberts JP, Prueksaritanost T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453–7

    Article  Google Scholar 

  7. Osowski CL, Dix SP, Lin LS, et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268–72

    Article  PubMed  CAS  Google Scholar 

  8. Kobayashi K, Ratain MJ, Fleming GF, et al. A phase I study of CYP3A4 modulation of oral etoposide with ketoconazole in patients with advanced cancer. Proc Am Soc Clin Oncol 1996; 15: 471a

    Google Scholar 

  9. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 1993; 67: 630–4

    Article  PubMed  CAS  Google Scholar 

  10. Lilleyman JS, Lennard L. Non-compliance with oral chemotherapy in childhood leukaemia. BMJ 1996; 313: 1219–20

    Article  PubMed  CAS  Google Scholar 

  11. Lau RC, Matsui D, Greenberg M, et al. Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. Med Pediatr Oncol 1998; 30: 85–90

    Article  PubMed  CAS  Google Scholar 

  12. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with oral chemotherapy as assessed by a novel oral technique. J Clin Oncol 1992; 10: 1007–13

    PubMed  CAS  Google Scholar 

  13. Lee C, Nicholson P, Souhami R, et al. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 1993; 67: 630–4

    Article  PubMed  CAS  Google Scholar 

  14. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drag therapy in patients with hematologic malignancy. J Clin Oncol 1987; 5: 1469–76

    PubMed  CAS  Google Scholar 

  15. Sullivan SD, Mozaffari E, Johnson ES, et al. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin Ther 1996; 18: 546–58

    Article  PubMed  CAS  Google Scholar 

  16. Liu G, Franssen E, Fitch M, et al. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–5

    PubMed  CAS  Google Scholar 

  17. Warrell RP, de-The H, Wang ZY, et al. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177–89

    Article  PubMed  CAS  Google Scholar 

  18. Rowley JD, Golomb HM, Dougherty C. 15/17 Translocation: a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; 1: 549–50

    Article  PubMed  CAS  Google Scholar 

  19. DeThe J, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558–61

    Article  CAS  Google Scholar 

  20. DeThe H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675–84

    Article  CAS  Google Scholar 

  21. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990; 8: 1913–21

    PubMed  CAS  Google Scholar 

  22. Kantarjian HM, Keating MJ, Walters RS, et al. Acute promyelocytic leukemia: M.D. Anderson Hospital experience. Am J Med 1986; 80: 789–97

    Article  PubMed  CAS  Google Scholar 

  23. Sanz MA, Jarque I, Martin G, et al. Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer 1988; 61: 7–13

    Article  PubMed  CAS  Google Scholar 

  24. Gralnick HR, Sultan C. Acute promyelocytic leukaemia: haemorrhagic manifestation and morphologic criteria. Br J Haematol 1975; 29: 373–6

    Article  PubMed  CAS  Google Scholar 

  25. Tabin CJ. Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell 1991; 66: 199–217

    Article  PubMed  CAS  Google Scholar 

  26. Sun GL, Huang YG, Chang XF, et al. Clinical study on all-trans retinoic acid in treatment of 544 cases of acute promyelocytic leukemia. Chin JHematol 1992; 13: 135–7

    Google Scholar 

  27. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704–9

    CAS  Google Scholar 

  28. Warrell Jr RP, Frankel SR, Miller Jr WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385–93

    Article  PubMed  Google Scholar 

  29. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–72

    PubMed  CAS  Google Scholar 

  30. Fenaux P, Castaigne S, Dombret H, et al. All-trans retinoic acid following by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176–81

    PubMed  CAS  Google Scholar 

  31. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multi-center randomized trial: European APL 91 Group. Blood 1993; 82: 3241–9

    PubMed  CAS  Google Scholar 

  32. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 1202–6

    PubMed  CAS  Google Scholar 

  33. Avvisati G, Lo Cocco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–8

    PubMed  CAS  Google Scholar 

  34. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–21

    CAS  Google Scholar 

  35. Tallman MS, Anderson JW, Schiffer CA, et al. All-trans retinoic acid in acute myelocytic leukemia. N Engl J Med 1997; 337: 1021–8

    Article  PubMed  CAS  Google Scholar 

  36. Chen ZX, Xue YQ, Zhang RI, et al. Aclinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–9

    PubMed  CAS  Google Scholar 

  37. Frankel SR, Eardley A, Lauwers G, et al. The ‘retinoic acid syndrome’ in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292–6

    PubMed  CAS  Google Scholar 

  38. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–90

    Google Scholar 

  39. Jackson GH, Taylor PR, Iqbal A, et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukemia in the elderly: a report of toxicity and efficacy. Leukemia 1997; 11: 1193–6

    Article  PubMed  CAS  Google Scholar 

  40. Schleyer E, Kuhn S, Ruhrs H, et al. Oral idarubicin pharmacokinetics —correlation of trough level with idarubicin area under curve. Leukemia 1997; 11 Suppl. 5: S15–21

    PubMed  CAS  Google Scholar 

  41. Schwendener RA, Horber DH, Odermatt B, et al. Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine. J Cancer Res Clin Oncol 1996; 122: 102–8

    Article  PubMed  CAS  Google Scholar 

  42. Okumura H, Yoshida T, Takamatsu H, et al. Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor. Int J Hematol 1997; 65: 263–8

    Article  PubMed  CAS  Google Scholar 

  43. Munshi NC, Tricot GJ. Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia. Ann Hematol 1997; 74: 111–5

    Article  PubMed  CAS  Google Scholar 

  44. Lancaster D, Lennard L, Lilleyman JS. Profile of non-compliance in lymphoblastic leukemia. Arch Dis Child 1997; 76: 365–6

    Article  PubMed  CAS  Google Scholar 

  45. Schmiegelow K, Glomstein A, Kristinsson J, et al. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol 1997; 19: 102–9

    Article  PubMed  CAS  Google Scholar 

  46. Mahoney Jr DH, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol 1998; 16: 246–54

    PubMed  CAS  Google Scholar 

  47. Lange BJ, Blatt J, Sather HN, et al. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Med Pediatr Oncol 1996; 27: 15–20

    Article  PubMed  CAS  Google Scholar 

  48. Winick N, Shuster JJ, Bowman WP, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 2803–11

    PubMed  CAS  Google Scholar 

  49. Morton AJ, Gooley T, Hansen JA, et al. Impact of pre-transplant interferon-alpha on outcome of unrelated donor marrow transplants for chronic myeloid leukemia (CML) in first chronic phase. Blood 1997; 90 Suppl. 1: 123a

    Google Scholar 

  50. Kantarjian HM, O’Brien S, Anderline P, et al. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069–81

    PubMed  CAS  Google Scholar 

  51. Saven A, Cheung WK, Smith I, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996; 14: 978–83

    PubMed  CAS  Google Scholar 

  52. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160–6

    PubMed  CAS  Google Scholar 

  53. Liliemark J, Albertioni F, Juliusson G, et al. A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.V. infusion, s.c. injection, and oral administration. Cancer Chemother Pharmacol 1996; 38: 536–40

    Article  PubMed  CAS  Google Scholar 

  54. Hassan M, Oberg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulfan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130–4

    Article  PubMed  CAS  Google Scholar 

  55. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls. Anticancer Res 1994; 14: 2363–70

    PubMed  CAS  Google Scholar 

  56. Vassal G, Gouyette A, Hartmann O, et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989; 24: 386–90

    Article  PubMed  CAS  Google Scholar 

  57. Grochow LB, Krivit W, Whitley CB, et al. Busulfan disposition in children. Blood 1990; 75: 1723–7

    PubMed  CAS  Google Scholar 

  58. Yeager AM, Wagner Jr JE, Graham ML, et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425–8

    PubMed  CAS  Google Scholar 

  59. Shaw PJ, Scharing CE, Brian RJ, et al. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994; 84: 2357–62

    PubMed  CAS  Google Scholar 

  60. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55–61

    Article  PubMed  CAS  Google Scholar 

  61. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–30

    PubMed  CAS  Google Scholar 

  62. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejections and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31–42

    PubMed  CAS  Google Scholar 

  63. Ljungman P, Hassan M, Bekassy AN, et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909–13

    Article  PubMed  CAS  Google Scholar 

  64. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055–60

    PubMed  CAS  Google Scholar 

  65. Schuler U, Schroer S, Kuhnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759–65

    PubMed  CAS  Google Scholar 

  66. Pawlowska AB, Blazar BR, Angelucci E, et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20: 915–20

    Article  PubMed  CAS  Google Scholar 

  67. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20 Suppl. 4: 18–25

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blood and Marrow Transplant Program, Oncology and Hematology Associates, and Saint Luke’s Hospital of Kansas City, 4401 Wornall Road, Kansas City, Missouri, 64111, USA

    Robert B. Geller (Medical Director) & Suzanne P. Dix

Authors
  1. Robert B. Geller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzanne P. Dix
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert B. Geller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Geller, R.B., Dix, S.P. Oral Chemotherapy Agents in the Treatment of Leukaemia. Drugs 58 (Suppl 3), 109–118 (1999). https://doi.org/10.2165/00003495-199958003-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958003-00015

Keywords

Search

Navigation